Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471

31

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Compass Therapeutics today announced the first patient has been dosed in its multi-center, open-label, first-in-human Phase 1 trial of CTX-471.

 

 

 

http://www.businesswire.com/news/home/20190708005106/en/Compass-Therapeutics-Announces-Patient-Dosed-Phase-1/